Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice

被引:6
作者
Sarin, PS
Talmadge, JE
Heseltine, P
Murcar, N
Gendelman, HE
Coleman, R
Kelsey, L
Beckner, S
Winship, D
Kahn, J
机构
[1] CEL SCI Corp, Vienna, VA 22182 USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[3] Univ So Calif, Dept Med, Los Angeles, CA USA
[4] San Francisco Gen Hosp, San Francisco, CA 94110 USA
[5] Dept Med, San Francisco, CA USA
关键词
HGP-30; HIV-1; vaccine; SCID mice;
D O I
10.1016/S0264-410X(98)00119-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Eleven HIV-1 seronegative subjects previously injected with an HIV-1 p17 synthetic peptide vaccine (HGP-30) were given two booster immunizations to evaluate memory cell responses and the ability to boost cellular and humoral immune responses. Five of 11 subjects showed a significant increase in their antibody titres to HGP-30 or p17 and 6/11 had T-cell proliferation responses to either HGP-30 or p17. HIV-1 virus challenge studies in SCID mice demonstrated that 39 of 50 mice (78%) receiving PBMC from 5 of the HGP-30 immunized subjects were protected from infection with a different strain of HIV-1 compared to 4 of 30 mice (13%) that received PBMC from 3 non-immunized subjects (p < 0.001). These studies show that booster immunizations with HGP-30 vaccine are safe and non-toxic and induce protective cell mediated immune responses. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:64 / 71
页数:8
相关论文
共 40 条
  • [11] EZZELL C, 1993, J NIH RES, V5, P59
  • [12] GAZZARD B, 1992, VACCINE RES, V1, P129
  • [13] Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120 - A randomized, double-blind trial
    Graham, BS
    Keefer, MC
    McElrath, MJ
    Gorse, GJ
    Schwartz, DH
    Weinhold, K
    Matthews, TJ
    Esterlitz, JR
    Sinangil, F
    Fast, PE
    Wright, PF
    Dolin, R
    Corey, L
    Belshe, RB
    Clements, ML
    Bolognesi, DP
    Stablein, DM
    Chernoff, D
    Duliege, AM
    Walker, CM
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (04) : 270 - +
  • [14] A MACROMOLECULAR MULTICOMPONENT PEPTIDE VACCINE PREPARED USING THE GLUTARALDEHYDE CONJUGATION METHOD WITH STRONG IMMUNOGENICITY FOR HIV-1
    HAMAJIMA, K
    BUKAWA, H
    FUKUSHIMA, J
    KAWAMOTO, S
    KANEKO, T
    SEKIGAWA, KI
    TANAKA, SI
    TSUKUDA, M
    OKUDA, K
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 77 (03): : 374 - 379
  • [15] HARRER E, 1993, 9 INT C AIDS BERL, P215
  • [16] Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection
    Harrer, T
    Harrer, E
    Kalams, SA
    Elbeik, T
    Staprans, SI
    Feinberg, MB
    Cao, YZ
    Ho, DD
    Yilma, T
    Caliendo, AM
    Johnson, RP
    Buchbinder, SP
    Walker, BD
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (07) : 585 - 592
  • [17] SCIENTIFIC AND SOCIAL-ISSUES OF HUMAN-IMMUNODEFICIENCY-VIRUS VACCINE DEVELOPMENT
    HAYNES, BF
    [J]. SCIENCE, 1993, 260 (5112) : 1279 - 1286
  • [18] Toward an understanding of the correlates of protective immunity to HIV infection
    Haynes, BF
    Pantaleo, G
    Fauci, AS
    [J]. SCIENCE, 1996, 271 (5247) : 324 - 328
  • [19] PROGRESS IN AIDS VACCINE DEVELOPMENT
    JOHNSTON, MI
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1995, 108 (04) : 313 - 317
  • [20] KAHN J, 1996, 11 INT C AIDS VANC